ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy
When any fetal blood group factor inherited from the father is not possessed by the mother, antepartum or intrapartum fetal-maternal bleeding may stimulate an immune reaction in the mother. Maternal immune reactions also can occur from blood product transfusion. The formation of maternal antibodies, or "alloimmunization," may lead to various degrees of transplacental passage of these antibodies into the fetal circulation. Depending on the degree of antigenicity and the amount and type of antibodies involved, this transplacental passage may lead to hemolytic disease in the fetus and neonate. Undiagnosed and untreated, alloimmunization can lead to significant perinatal morbidity and mortality. Advances in Doppler ultrasonography have led to the development of noninvasive methods of management of alloimmunization in pregnant women. Together with more established protocols, Doppler ultrasound evaluation may allow for a more thorough and less invasive workup with fewer risks to the mother and fetus. Prevention of alloimmunization is addressed in another Practice Bulletin ().
American College of Obstetrics & Gynecology Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy
2018 Mar;131(3):e82-e90
American College of Obstetrics & Gynecology Practice Bulletin No. 183: Postpartum Hemorrhage
2017 Oct;130(4):e168-e186
American College of Obstetrics & Gynecology Practice Bulletin No. 181: Prevention of Rh D Alloimmunization
2017 Aug;130(2):e57-e70.
American College of Obstetrics & Gynecology Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy
July 2018 - Volume 132 - Issue 1 - p e18–e34
American College of Obstetrics & Gynecology Practice Bulletin No. 196 Summary: Thromboembolism in Pregnancy
July 2018 - Volume 132 - Issue 1 - p 243–248
ACOG Committee Opinion: Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices